98%
921
2 minutes
20
Objective: Although many animal and human studies have been performed, the exact mechanisms of action whereby modafinil promotes wakefulness are still not completely understood. We aimed to investigate the functional effects of modafinil on motor cortex excitability in patients with narcolepsy by means of transcranial magnetic stimulation (TMS) techniques.
Methods: In a double-blind and placebo-controlled design, 24 drug-naive narcoleptic patients with cataplexy and 20 control subjects were administered modafinil or placebo over a period of 4 weeks. TMS was performed twice during the awake state before and at the end of treatment; measures of cortical excitability included central motor conduction time, resting motor threshold, short latency intracortical inhibition (SICI) and intracortical facilitation to paired-TMS. TMS measures were correlated with the conventional neurophysiological method of Multiple Sleep Latency Test (MSLT) and the subjective Epworth Sleepiness Scale (ESS).
Results: As previously reported, motor threshold and SICI were significantly increased in patients with narcolepsy; modafinil reversed this cortical hypoexcitability, but only SICI differences reached statistical significance. The Spearman rank correlation analysis revealed the highest correlation between SICI and the MSLT; a positive correlation was also found between SICI and the ESS, as well as between RMT and both measures of daytime sleepiness.
Conclusions: This represents the first report investigating effects of modafinil on cortical excitability in human narcolepsy. Since SICI is thought to be directly related to GABA(A) intracortical inhibitory activity, we demonstrated that the dose of modafinil that induces a satisfactory wakefulness-promoting response in narcoleptic patients also causes decrease in GABAergic transmission.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.sleep.2010.05.007 | DOI Listing |
Sleep Breath
August 2025
Department of Psychiatry, Sleep Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Study Objectives: This study aimed to assess and quantify rapid eye movement (REM) sleep electromyographic (EMG) activity in narcolepsy patients.
Methods: The study involved 95 participants, including 25 with narcolepsy type 1 (NT1), 36 with narcolepsy type 2 (NT2), and 34 healthy controls (HC). We visually analyzed phasic, tonic, and "any" muscle activity for the submentalis (SM) and phasic for the anterior tibialis (AT) by both 3-s REM mini-epochs (3sRME) and 30-s REM epochs (30sRE) methods.
J Sleep Res
August 2025
IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Narcolepsy type 1 is a neurological disorder typically emerging in childhood or adolescence, characterised by excessive daytime sleepiness, cataplexy and rapid eye movement sleep-related symptoms. Beyond its core features, increasing evidence suggests an impact on socio-cognitive development, including difficulties in understanding others' mental states. In this study, we aimed to clarify whether such impairments extend to more basic emotional processes.
View Article and Find Full Text PDFSleep Med
May 2025
CHRU Gui de Chauliac, 80 Avenue Augustin Fliche, 34295, Montpellier, France. Electronic address:
Background: Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1). Pitolisant is a histamine 3 receptor antagonist/inverse agonist that reduces EDS and cataplexy in patients with narcolepsy.
Methods: We performed a prospective 5-year follow-up, non-interventional study of adults with NT1 and NT2 receiving pitolisant.
JMIR Public Health Surveill
January 2025
Centre of Sleep Medicine and Epileptology Barmelweid, Klinik Barmelweid AG, Aargau, Switzerland.
Background: Stimulants are potent treatments for central hypersomnolence disorders or attention-deficit/hyperactivity disorders/attention deficit disorders but concerns have been raised about their potential negative consequences and their increasing prescription rates.
Objective: We aimed to describe stimulant prescription trends in Switzerland from 2014 to 2021. Second, we aimed to analyze the characteristics of individuals who received stimulant prescriptions in 2021 and investigate the link between stimulant prescriptions and hospitalization rates in 2021, using hospitalization as a potential indicator of adverse health outcomes.
Clin Auton Res
April 2025
Unité du Sommeil, Centre de Compétences Narcolepsie Et Hypersomnie Rare, Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse, France.